Senators expand probe of Pfizer, Lilly DTC platforms
| | Today’s Big News Mar 14, 2025 |
| Thursday, April 3, 2025 | 11am ET / 8am PT Join us for an insightful webinar on the latest advancements in cell and gene therapy, focusing on the innovative Cas9-CLIPT (Cleaved, Linearized with Protein Template) technology. Learn more about this groundbreaking technology designed to improve the efficiency of genome editing. Register now.
|
|
| | | By Fraiser Kansteiner The University of Pennsylvania and Roche’s Genentech unit have settled a lawsuit UPenn originally brought to a Delaware federal court in 2022, which accused the drugmaker of infringing a now-expired patent on methods of tumor treatment pioneered at the university’s Abramson Cancer Center. |
|
|
|
| By James Waldron Sutro Biopharma is undergoing a seismic shake-up—jettisoning its CEO, half of its workforce, its lead candidate and its manufacturing facility in a major bid to save cash. |
| By Andrea Park Several months after a group of senators sent letters to Pfizer and Eli Lilly investigating their respective direct-to-consumer telehealth platforms, the lawmakers are now directing similar queries toward several of the platforms’ partners. |
| By Kevin Dunleavy In a year in which he faced down a challenge from activist investor Starboard Value, Pfizer CEO Albert Bourla received a total compensation increase of 14%. |
| By Darren Incorvaia,Zoey Becker Gilead’s Sandra Patterson has “decided to leave the company” after two years in the SVP corporate controller and chief accounting officer role, according to a company filing. Patterson was also Gilead’s principal accounting officer. In her place, the company’s board tapped Diane Wilfong in an interim position amid the search for a permanent successor. |
| By Conor Hale The company’s Vivistim system targets the body’s vagus nerves in the neck, delivering electrical pulses during exercise regimens to help retrain a damaged brain. |
| By James Waldron With Concentra Biosciences expanding its stock influence on Pliant Therapeutics and Acelyrin, the two biotechs have shored up their corporate defences against a potential acquisition. |
| By Zoey Becker The FDA chief counsel pick quickly attracted controversy due to her prior defense of medical abortion under the Biden administration's Department of Justice. |
| By Andrea Park AstraZeneca is hopping aboard the pickleball craze as its serves up a new marketing push for its asthma med Fasenra. |
| By Fraiser Kansteiner Following a fire at a Bayer executive’s home earlier this month, eight agencies—including the FBI—are now looking into the blaze as a possible arson, according to reports. The fire originally broke out around 7:30 a.m. on March 4 at an “occupied residence” in the New Jersey borough of Madison, the Morris County Prosecutor’s Office told multiple news outlets this week. |
| By Darren Incorvaia An oral small molecule from New York-based biotech Oligomerix curbed the tangling of tau protein in the brains of mice that model a rare neurological disease. |
Fierce podcasts Don’t miss an episode |
| | | This week on "The Top Line," we dissect the unprecedented revenue growth enjoyed by many major pharma companies in 2024’s fourth quarter. |
|
|---|
|
|
Wednesday, April 9, 2025 | 10am ET / 7am PT Learn the key steps for successfully entering Japan’s pharmaceutical market. This webinar covers regulatory requirements, compliance strategies, supply chain best practices, and common challenges. Gain expert insights to navigate this high-potential market with confidence. Don’t miss out—register now to secure your spot!
|
|
| Whitepaper Read about four trends that will shape the innovations, therapies, & market landscape in oncology during 2025 & beyond. Presented by Blue Matter, strategic consultants in the life sciences |
| Whitepaper Discover how to revolutionize your vaccine trials with Avacare's latest white paper. Gain exclusive access to innovative, data-driven recruitment strategies that ensure diverse, efficient, and high-quality vaccine trials. Sponsored by: Avacare Clinical Research Network |
| Whitepaper Develop your CAR molecule faster Sponsored by: Cell Signaling Technology |
| | |
|
